血管紧张素Ⅱ对骨髓间充质干细胞在缺血缺氧条件下Bcl-2和Bax表达的影响
发布时间:2018-10-14 17:29
【摘要】:研究背景:干细胞移植技术是近年来发展迅速的改善心功能的重要治疗手段,其中研究最多的是骨髓间充质干细胞(Bone Mesenchymal stemcells, BMSCs)。但是,它也面临着一系列的挑战,其中最重要的是移植后干细胞在梗死区的生存问题,90%以上的BMSCs在移植后数天内就会死亡。因此,如何提高移植后BMSCs的存活率,是提高缺血性心脏病干细胞治疗的关键,也是目前干细胞移植治疗亟待解决的问题。血管紧张素Ⅱ(AngiotensinⅡ, AngⅡ)是肾素-血管紧张素-醛固酮系统(reninangiotensin aldosterone system, RAAS)中重要的生物活性物质,在心血管疾病的发生发展中发挥重要作用,心肌梗死后机体可产生大量的AngⅡ,AngⅡ对移植后BMSCs存活的影响如何有待于进一步阐明。 目的:通过该研究探讨血管紧张素Ⅱ预处理对缺血缺氧条件下BMSCs的Bcl-2和Bax的表达的影响,从而寻求减少BMSCs在缺血缺氧环境中凋亡的更好机制。 方法:以缺氧无血清条件模拟心肌梗死后的缺血缺氧微环境。提取SD大鼠的BMSCs进行传原代培养,传代后取生长状态良好的BMSCs进行缺血缺氧处理,细胞活力采用CCK-8试剂盒测定,,再分别加入不同浓度的血管紧张素Ⅱ培养24小时,提取BMSCs的总RNA进行RT-PCR检测Bcl-2及Bax的表达情况。 结果:与对照组相比,缺血缺氧组BMSCs的细胞活力明显下降(P0.01);与单纯缺血缺氧组比较,加入血管紧张素Ⅱ组的BMSCs Bcl-2的表达上调(P0.01),Bax的表达下调(P0.01),Bcl-2/Bax比值增大(P0.01),0.1μm/L的血管紧张素Ⅱ对Bcl-2和Bax的表达影响较0.01μm/L显著(P0.05),而与1μm/L血管紧张素Ⅱ比较无显著差异(P0.05)。 结论:以缺氧无血清条件模拟细胞缺血缺氧条件下BMSCs的增殖和细胞活力明显下降;正常条件下培养的BMSCs不表达或低表达凋亡相关基因Bcl-2和Bax;血管紧张素Ⅱ可增强缺血缺氧条件下BMSCs的抗凋亡能力,这一过程可能是通过升高Bcl-2/Bax比值来实现的。
[Abstract]:Background: stem cell transplantation is an important therapeutic method to improve cardiac function rapidly in recent years, in which bone marrow mesenchymal stem cell (Bone Mesenchymal stemcells, BMSCs).) is the most studied. However, it also faces a series of challenges, the most important of which is the survival of stem cells in the infarcted area after transplantation. More than 90% of BMSCs will die within days after transplantation. Therefore, how to improve the survival rate of BMSCs after transplantation is the key to improve the stem cell therapy of ischemic heart disease. Angiotensin 鈪
本文编号:2271129
[Abstract]:Background: stem cell transplantation is an important therapeutic method to improve cardiac function rapidly in recent years, in which bone marrow mesenchymal stem cell (Bone Mesenchymal stemcells, BMSCs).) is the most studied. However, it also faces a series of challenges, the most important of which is the survival of stem cells in the infarcted area after transplantation. More than 90% of BMSCs will die within days after transplantation. Therefore, how to improve the survival rate of BMSCs after transplantation is the key to improve the stem cell therapy of ischemic heart disease. Angiotensin 鈪
本文编号:2271129
本文链接:https://www.wllwen.com/yixuelunwen/shiyanyixue/2271129.html
最近更新
教材专著